Strides Shasun has received approval from the US health regulator for potassium citrate extended release tablets used to prevent certain types of kidney stones.
The company said in a BSE filing today that it has received approval from the United States Food and Drug Administration (USFDA) for potassium citrate extended release tablets USP 5 mEq, 10 mEq and 15 mEq.
Strides Shasun said it will be the second generic player to commercialise the product and will launch it immediately. Citing IMS sales data, the company said the US market for the approved product is approximately $110 million.
The company shares were trading 2.79 per cent higher at Rs 967.55 per scrip on the BSE